Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

NCT03278314 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: tezacaftor/ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated